Gilead Sciences sets aside $200 million to resolve HIV drug probe
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
Yahoo Finance2d
Gilead Sciences, Inc. (GILD)
FOSTER CITY, Calif., February 24, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...
Barchart on MSN2d
Gilead Sciences - Leader in HIV Medicines
Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...
Business Wire20d
European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...
The Business Journals1mon
How key drugs boosted Gilead — and how the Inflation Reduction Act could deliver a billion-dollar hit
Gilead Sciences Inc.'s sales exceeded Wall ... year via drug-pricing provisions in the Inflation Reduction Act. The Foster City-based company (Nasdaq: GILD) said it earned $480 million in 2024 ...
Morningstar2d
Gilead Sciences - Women's History Month Celebrated With Its Team
Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. Originally published by Gilead Sciences.
FierceBiotech26d
Gilead loses interest in Arcus' kidney cancer rival to Merck's Welireg
Gilead Sciences has defied analysts’ expectations ... Still, Gilead kept an interest in Arcus' work, with the Foster City, California-based pharma plugging a further $320 million into its ...
Investing4d
Gilead reports high efficacy in HIV and HBV treatment study
FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD), a prominent player in the biotechnology industry with a market capitalization of $142.5 billion and annual revenue of $28.75 billion ...
Nasdaq9d
How Is Gilead Sciences' Stock Performance Compared to Other Pharmaceutical Stocks?
Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need. The Foster City, California-based company ...
CSR Wire24d
The Centrifuge Sessions: How Gilead Sciences Is Impacting Autoimmune Disease
Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops ...